RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
0.9483
-0.0009 (-0.09%)
At close: Apr 22, 2026, 4:00 PM EDT
0.9573
+0.0090 (0.95%)
After-hours: Apr 22, 2026, 5:22 PM EDT
RenovoRx Revenue
In the year 2025, RenovoRx had annual revenue of $1.12M with 2,511.63% growth. RenovoRx had revenue of $238.00K in the quarter ending December 31, 2025, with 453.49% growth.
Revenue (ttm)
$1.12M
Revenue Growth
+2,511.63%
P/S Ratio
38.04
Revenue / Employee
$66,059
Employees
17
Market Cap
42.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.12M | 1.08M | 2,511.63% |
| Dec 31, 2024 | 43.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Atara Biotherapeutics | 120.77M |
| Aligos Therapeutics | 2.19M |
| Werewolf Therapeutics | 1.14M |
| Rallybio | 858.00K |
| Hyperion DeFi | 813.46K |
| Actinium Pharmaceuticals | 90.00K |
RNXT News
- 8 days ago - Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting - GlobeNewsWire
- 14 days ago - RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum - GlobeNewsWire
- 21 days ago - RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 - GlobeNewsWire
- 23 days ago - RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 27 days ago - RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment - GlobeNewsWire
- 4 weeks ago - RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement - GlobeNewsWire
- 4 weeks ago - RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET - GlobeNewsWire
- 5 weeks ago - RenovoRx Announces $10 Million at Market Private Placement - GlobeNewsWire